Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK
Prevention trials represent a critical frontier in Alzheimer's disease research, aiming to intervene before clinical symptoms appear. AAIC 2026 features extensive programming on prevention strategies, including pharmacological and lifestyle interventions, genetic risk reduction, and population-level prevention approaches.
- DIAN-TU: Updates on tau-targeted and amyloid-targeted arms
- API ADAD: Colombian kindred prevention program
- Generation Study: APP and presenilin mutation carriers
- A4 Study: Anti-amyloid therapy in preclinical AD
- LEARN Study: Natural history in preclinical AD
- EXERT: Exercise intervention in cognitively normal adults
¶ Multi-Domain Interventions
- FINGER Trial: Finnish Geriatric Intervention Study
- MAPT: Multidomain Alzheimer Preventive Trial
- POINTER: US-based multidomain intervention
- TRAILBLAZER-ALZ 3: Donanemab in preclinical AD
- AHEAD 3-45: Lecanemab in preclinical AD with elevated amyloid
- Cognitively Normal with Amyloid: Various anti-amyloid approaches
- SPRINT-MIND: Blood pressure control and cognitive outcomes
- ACTC-EMERGE: Vascular contributions to dementia prevention
The Lancet Commission on dementia prevention identifies 12 modifiable risk factors:
- Hearing loss: Hearing aid use and social engagement
- Less education: Cognitive reserve building
- Traumatic brain injury: Prevention and management
- Hypertension: Blood pressure control
- Alcohol: Moderate consumption
- Obesity: Weight management
- Smoking: Smoking cessation
- Depression: Treatment and prevention
- Social isolation: Community engagement
- Physical inactivity: Exercise recommendations
- Diabetes: Metabolic management
- Sleep: Sleep hygiene and disorder treatment
- Aerobic exercise and cognitive benefits
- Resistance training effects
- Combined exercise modalities
- Speed of processing training
- Memory and executive function
- Computerized vs. traditional approaches
- MIND Diet: Mediterranean-DASH Intervention
- Ketogenic approaches
- Time-restricted eating
- Down Syndrome: Alzheimer's prevention in trisomy 21
- Autosomal Dominant: Genetic counseling and prevention
- African American communities: Inclusion in prevention trials
- Hispanic/Latino populations: Addressing health disparities
- APOE4 carriers: Targeted prevention strategies
- Centiloid standardization
- Threshold determination for intervention
- Longitudinal amyloid changes
- Temporal lobe tau as endpoint
- Tau progression rates
- Correlation with cognitive decline
- "Update on DIAN-TU: Lessons Learned and Future Directions"
- "Lifestyle Prevention: Evidence and Implementation"
- "Biomarker Endpoints in Prevention Trials"
- "Recruitment Strategies for Prevention Trials"
- "Statistical Methods for Slow Decline Endpoints"